Vascutan Plus^®

Vascutan Plus combines the Irbesartan and Hydrochlorothiazide molecules in a tablet for oral administration, designed to optimize blood pressure control in patients with hypertension who have not responded sufficiently to a single drug. This medication offers the benefit of two antihypertensive agents with complementary mechanisms of action to improve therapeutic efficacy.

Vascutan Plus is indicated for the treatment of arterial hypertension in patients who require combination therapy. It is suitable for arterial hypertension (especially in patients who have not achieved the desired control with a single agent), cardiovascular risk management (effective blood pressure control helps reduce the risk of cardiovascular events, including stroke and myocardial infarction) and long-term management (suitable for patients who require combination therapy for sustained blood pressure control).

Irbesartan is an angiotensin II receptor antagonist that helps relax the blood vessels. Hydrochlorothiazide is a thiazide diuretic that helps reduce blood volume, which lowers blood pressure and reduces the workload of the heart.

Dosage should be adjusted individually according to the patient’s blood pressure response and tolerance. Typical starting dose: one tablet of Irbesartan 150 mg / Hydrochlorothiazide 12.5 mg once daily. May be increased to Irbesartan 300 mg / Hydrochlorothiazide 25 mg according to the patient’s need and tolerance. Can be taken with or without food.

The combination of Irbesartan and Hydrochlorothiazide improves efficacy in lowering blood pressure more than either component alone. Reduces the number of tablets needed, improving the patient’s adherence to treatment.

Evaluate blood pressure and renal function before starting treatment and monitor regularly. Start treatment only after evaluating the patient’s fluid volume and electrolyte balance. Adjust the dose based on the patient’s blood pressure response and tolerance.

Monitor electrolyte levels and renal function due to the risk of dehydration and electrolyte imbalances caused by the diuretic. Caution in patients with renal or hepatic diseases. Contraindicated in patients with hypersensitivity to any component of the product, anuria, or hypersensitivity to sulfonamide-derived drugs. Do not coadminister aliskiren with Vascutan Plus in patients with diabetes.

Vascutan Plus is available as Irbesartan 150 mg / Hydrochlorothiazide 12.5 mg and Irbesartan 300 mg / Hydrochlorothiazide 25 mg, in a box of 30 or 100 tablets, following the United States Pharmacopeia standard.

Vascutan Plus is manufactured according to the strict specifications of the United States Pharmacopeia to ensure consistency and superior quality. Crassula Pharma certifies that all its products are manufactured in accordance with GMP parameters.